COLLEGE OF MEDICINE AND HEALTH
Medicine, Nursing and Allied Health Professions

Loading content
 John Dennis

John Dennis

Postgraduate Research Assistant and PhD student

 07734 940921

 South Cloisters 

 

South Cloisters, University of Exeter, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK

John is a PhD student and graduate researcher at the University of Exeter Medical School. He joined the Health Statistics group as a part-time PhD student in October 2014, under Professor William Henley, Dr Beverley Shields and Professor Andrew Hattersley. In January 2018 he joined Professor Hattersley’s diabetes research team full-time.

His research focuses on developing a stratified or ‘precision’ approach to drug therapy in type 2 diabetes, a condition for which there are many different drug options but little guidance to help clinicians and patients choose between them. John is applying advanced statistical methods to better understand the benefits and risks of each drug option, in particular which patients are likely to have the best response and/or lowest risk of side effects, and to what extent response and side-effects go hand-in-hand. He was awarded runner-up in the Diabetes UK Type 2 Diabetes Research Prize in 2017 and won the Diabetes UK Lily Clinical Science Poster Award in 2015.

John is also developing a more general methodological framework for precision medicine research using as a first discovery step ‘big’ data from routine clinical practice (the UK’s CPRD), followed by validation of findings in individual participant data from existing randomised trials available from Clinical Study Data Request and the YODA Project.

John trained at the London School of Hygiene & Tropical Medicine and has 5 years’ experience as a health researcher in the financial services industry, where he specialised in longevity modelling. He has also worked a research analyst for the Cancer Council in Australia and for the NHS in the UK. Across these roles he developed his interest in applied statistical research and chronic disease epidemiology that led him to Professor Hattersley’s team at the University of Exeter.

Qualifications

MSc Control of Infectious Diseases (London School of Hygiene and Tropical Medicine)

BSc (Hons) Psychology (University of Nottingham)

Research

Research interests

  • Precision/Stratified medicine: Stratification of therapy in type 2 diabetes as part of the MRC-funded APBI Stratification and Extreme Response Mechanism IN Diabetes (MASTERMIND) consortium
  • Joint longitudinal-survival modelling
  • Clinical prediction models
  • Longevity modelling
  • Methods to strengthen inference from routine clinical practice databases

Research projects

MRC-funded APBI Stratification and Extreme Response Mechanism IN Diabetes (MASTERMIND) consortium.

Key publications | Publications by category | Publications by year

Key publications


Dennis J, Henley W, Weedon M, Lonergan M, Rodgers L, Jones A, Hamilton W, Sattar N, Janmohamed S, Holman R, et al (In Press). Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and individual trial data. Diabetes Care Full text.
Curtis HJ, Dennis JM, Shields BM, Walker AJ, Bacon S, Hattersley AT, Jones AG, Goldacre B (In Press). Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes Obes Metab, 20(9), 2159-2168. Abstract.  Author URL.  Full text.
Dennis JM, Henley WE, Weedon MN, Rodgers LR, Jones AG, Pearson ER, Hattersley AT, Shields BM (2018). Are the new drugs better? Changing UK prescribing of Type 2 diabetes medications and effects on HbA1c and weight, 2010 to 2016.  Author URL.  Full text.
Kimmitt RA, Dennis JM, Weedon M, Rodgers LR, Jones AG, Pearson ER, Hattersley AT, Oram RA, Shields BM (2018). Higher estimated glomerular filtration rate (eGFR) is associated with improved glycaemic response to sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with Type 2 diabetes and normal renal function: a MASTERMIND study.  Author URL.
Dennis J, Shields B, Hill A, Knight B, McDonald T, Rodgers L, Weedon M, Henley W, Sattar N, Holman R, et al (2018). Precision medicine in Type 2 diabetes: Clinical markers of insulin resistance are associated with altered short and long-term glycemic response to DPP4-inhibitor therapy. Diabetes Care Full text.
Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Sattar NA, Holman RR, Pearson ER, Hattersley AT, et al (2017). A calculator to predict durability of HbA(1c) response with DPP4 inhibitors, sulfonylureas and thiazolidinediones: a MASTERMIND precision medicine study.  Author URL.

Publications by category


Journal articles

Dennis J, Henley W, Weedon M, Lonergan M, Rodgers L, Jones A, Hamilton W, Sattar N, Janmohamed S, Holman R, et al (In Press). Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and individual trial data. Diabetes Care Full text.
Curtis HJ, Dennis JM, Shields BM, Walker AJ, Bacon S, Hattersley AT, Jones AG, Goldacre B (In Press). Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes Obes Metab, 20(9), 2159-2168. Abstract.  Author URL.  Full text.
Dennis J, Shields B, Hill A, Knight B, McDonald T, Rodgers L, Weedon M, Henley W, Sattar N, Holman R, et al (2018). Precision medicine in Type 2 diabetes: Clinical markers of insulin resistance are associated with altered short and long-term glycemic response to DPP4-inhibitor therapy. Diabetes Care Full text.
Harris JD, Little CJL, Dennis JM, Patteson MW (2017). Heart rate turbulence after ventricular premature beats in healthy Doberman pinschers and those with dilated cardiomyopathy. J Vet Cardiol, 19(5), 421-432. Abstract.  Author URL.
Dennis J, Crayford T (2015). Parliamentary privilege—mortality in members of the Houses of Parliament compared with the UK general population: retrospective cohort analysis, 1945-2011. BMJ, h6563-h6563.

Conferences

Dennis JM, Henley WE, Weedon MN, Rodgers LR, Jones AG, Pearson ER, Hattersley AT, Shields BM (2018). Are the new drugs better? Changing UK prescribing of Type 2 diabetes medications and effects on HbA1c and weight, 2010 to 2016.  Author URL.  Full text.
Kimmitt RA, Dennis JM, Weedon M, Rodgers LR, Jones AG, Pearson ER, Hattersley AT, Oram RA, Shields BM (2018). Higher estimated glomerular filtration rate (eGFR) is associated with improved glycaemic response to sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with Type 2 diabetes and normal renal function: a MASTERMIND study.  Author URL.
Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Sattar NA, Holman RR, Pearson ER, Hattersley AT, et al (2017). A calculator to predict durability of HbA(1c) response with DPP4 inhibitors, sulfonylureas and thiazolidinediones: a MASTERMIND precision medicine study.  Author URL.
Dennis JM, Shields BM, Henley WE, Knight BA, McDonald TJ, Hill AV, Weedon MN, Rodgers LR, Hattersley AT, Jones AG, et al (2017). Clinical markers of insulin resistance predict reduced glycaemic response with DPP4-inhibitors: a MASTERMIND stratified medicine study.  Author URL.
Dennis JM, Henley WE, Weedon M, Lonergan M, Jones AG, Sattar N, Holman RR, Pearson ER, Hattersley AT, Shields BM, et al (2017). Development of an online risk calculator to predict durability of good glycaemic control with sulfonylurea and thiazolidinedione therapy: a MASTERMIND stratified medicine study.  Author URL.
Shields BM, Dennis JM, Henley W, Weedon M, Lonergan M, Rodgers L, Jones AG, Holman RR, Pearson ER, Hattersley AT, et al (2016). Personalising therapy in type 2 diabetes: the effect of BMI and sex on glycaemic response and side effects to sulphonylureas and thiazolidinediones.  Author URL.
Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Holman RR, Pearson ER, Hattersley AT, Shields BM, et al (2016). Personalizing Therapy in Type 2 Diabetes: the Effect of BMI and Gender on Response and Side Effects to Sulfonylureas and Thiazolidinediones.  Author URL.
Dennis JM, Hattersley AT, Henley WE, Jones AG, Pearson ER, Shields BM (2016). Stratification using gender and body mass index (BMI) can predict side-effect risk in people with Type 2 diabetes initiating thiazolidinediones but not sulphonylureas: a MASTERMIND study.  Author URL.  Full text.
Dennis JM, Hattersley AT, Weedon M, Angwin C, Rodgers L, Pearson ER, Henley WE, Shields BM (2015). Development of oedema is associated with an improved glycaemic response in patients initiating thiazolidinediones: a MASTERMIND study.  Author URL.  Full text.
Dennis JM, Hattersley AT, Weedon M, Angwin CD, Rodgers L, Pearson ER, Henley WE, Shields BM (2015). Patients who develop oedema on initiating thiazolidinedione therapy have an improved glycaemic response: a MASTERMIND study.  Author URL.  Full text.

Publications by year


In Press

Dennis J, Henley W, Weedon M, Lonergan M, Rodgers L, Jones A, Hamilton W, Sattar N, Janmohamed S, Holman R, et al (In Press). Sex and BMI alter the benefits and risks of sulfonylureas and thiazolidinediones in type 2 diabetes: a framework for evaluating stratification using routine clinical and individual trial data. Diabetes Care Full text.
Curtis HJ, Dennis JM, Shields BM, Walker AJ, Bacon S, Hattersley AT, Jones AG, Goldacre B (In Press). Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes Obes Metab, 20(9), 2159-2168. Abstract.  Author URL.  Full text.

2018

Dennis JM, Henley WE, Weedon MN, Rodgers LR, Jones AG, Pearson ER, Hattersley AT, Shields BM (2018). Are the new drugs better? Changing UK prescribing of Type 2 diabetes medications and effects on HbA1c and weight, 2010 to 2016.  Author URL.  Full text.
Kimmitt RA, Dennis JM, Weedon M, Rodgers LR, Jones AG, Pearson ER, Hattersley AT, Oram RA, Shields BM (2018). Higher estimated glomerular filtration rate (eGFR) is associated with improved glycaemic response to sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with Type 2 diabetes and normal renal function: a MASTERMIND study.  Author URL.
Dennis J, Shields B, Hill A, Knight B, McDonald T, Rodgers L, Weedon M, Henley W, Sattar N, Holman R, et al (2018). Precision medicine in Type 2 diabetes: Clinical markers of insulin resistance are associated with altered short and long-term glycemic response to DPP4-inhibitor therapy. Diabetes Care Full text.

2017

Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Sattar NA, Holman RR, Pearson ER, Hattersley AT, et al (2017). A calculator to predict durability of HbA(1c) response with DPP4 inhibitors, sulfonylureas and thiazolidinediones: a MASTERMIND precision medicine study.  Author URL.
Dennis JM, Shields BM, Henley WE, Knight BA, McDonald TJ, Hill AV, Weedon MN, Rodgers LR, Hattersley AT, Jones AG, et al (2017). Clinical markers of insulin resistance predict reduced glycaemic response with DPP4-inhibitors: a MASTERMIND stratified medicine study.  Author URL.
Dennis JM, Henley WE, Weedon M, Lonergan M, Jones AG, Sattar N, Holman RR, Pearson ER, Hattersley AT, Shields BM, et al (2017). Development of an online risk calculator to predict durability of good glycaemic control with sulfonylurea and thiazolidinedione therapy: a MASTERMIND stratified medicine study.  Author URL.
Harris JD, Little CJL, Dennis JM, Patteson MW (2017). Heart rate turbulence after ventricular premature beats in healthy Doberman pinschers and those with dilated cardiomyopathy. J Vet Cardiol, 19(5), 421-432. Abstract.  Author URL.

2016

Shields BM, Dennis JM, Henley W, Weedon M, Lonergan M, Rodgers L, Jones AG, Holman RR, Pearson ER, Hattersley AT, et al (2016). Personalising therapy in type 2 diabetes: the effect of BMI and sex on glycaemic response and side effects to sulphonylureas and thiazolidinediones.  Author URL.
Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Holman RR, Pearson ER, Hattersley AT, Shields BM, et al (2016). Personalizing Therapy in Type 2 Diabetes: the Effect of BMI and Gender on Response and Side Effects to Sulfonylureas and Thiazolidinediones.  Author URL.
Dennis JM, Hattersley AT, Henley WE, Jones AG, Pearson ER, Shields BM (2016). Stratification using gender and body mass index (BMI) can predict side-effect risk in people with Type 2 diabetes initiating thiazolidinediones but not sulphonylureas: a MASTERMIND study.  Author URL.  Full text.

2015

Dennis JM, Hattersley AT, Weedon M, Angwin C, Rodgers L, Pearson ER, Henley WE, Shields BM (2015). Development of oedema is associated with an improved glycaemic response in patients initiating thiazolidinediones: a MASTERMIND study.  Author URL.  Full text.
Dennis J, Crayford T (2015). Parliamentary privilege—mortality in members of the Houses of Parliament compared with the UK general population: retrospective cohort analysis, 1945-2011. BMJ, h6563-h6563.
Dennis JM, Hattersley AT, Weedon M, Angwin CD, Rodgers L, Pearson ER, Henley WE, Shields BM (2015). Patients who develop oedema on initiating thiazolidinedione therapy have an improved glycaemic response: a MASTERMIND study.  Author URL.  Full text.

John_Dennis Details from cache as at 2018-10-16 12:38:16

Refresh publications

Awards

  • Poster prize runner-up. Statistical analysis of multi-outcome data conference, 2017
  • Diabetes UK Type 2 diabetes research award runner-up. Diabetes UK professional conference, 2017
  • Diabetes UK Lily Clinical Science Poster Award, Diabetes UK professional conference, 2015

Media Coverage

Feb 2018: Precision medicine in type 2 diabetes: Insulin resistance markers associated with DPP-IV inhibitor response in type 2 diabetes

Feb 2018: Diabetes: Clinical markers of glycaemic response to DPP4 inhibitor therapy

Dec 2015: New perk for MPs: longer life

Back | Edit Profile